95% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Neurol.
Sec. Neurological Biomarkers
Volume 16 - 2025 | doi: 10.3389/fneur.2025.1551239
Metabolomic analysis reveals trimethylamine N-oxide as a biomarker for poor outcome of severe spontaneous intracerebral hemorrhage patients receiving surgical treatment
Provisionally accepted
Xinguo Sun 1,2 Kaige Zheng 3,4
Shanjun Wang 1,5
Yunzhao Chen 1,6 Hongen Liu 2 Xindong Gu 2 Zitong Wu 2 Hui Lu 2
Shuo Wang 3,4*
Qingyuan Liu 3,4*
Zengguang Wang 1*- 1 Neurosurgery, Tianjin Medical University General Hospital, Tianjin, China
- 2 Neurosurgery, Binzhou People’s Hospital, Binzhou, Shandong Province, China
- 3 Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
- 4 China National Clinical Research Center for Neurological Diseases, Beijing, China
- 5 Neurosurgery, Yidu Central Hospital of Weifang, Weifang, Shandong Province, China
- 6 Neurosurgery, Inner Mongolia Autonomous Region People's Hospital, Hohhot, China
Background and objectives: Patients suffering from severe spontaneous intracerebral hemorrhage (SSICH) are at high risk of cardiocerebrovascular diseases postoperatively, which hugely affect patients' long-term outcomes. Metabolic features could reflect the pathological change of the cardiocerebrovascular system and might serve as biomarkers for evaluating the risk of poor outcomes in SSICH patients. The current study aimed to find the early-warning biomarkers for poor outcomes in SSICH patients after surgery.Methods: SSICH patients receiving surgical treatment from a referring hospital were prospectively included and formed the primary cohort after propensity score matching.The primary outcome is poor 180 days after hemorrhage (modified Rankin scale ≥4).Metabolomics analysis on 3-, 7-and 30-day serum and cerebrospinal fluid samples after surgery revealed the dysregulated metabolites of SSICH patients within the primary cohort. Within the validation cohort of SSICH patients receiving surgical treatment from a multicenter, prospective cohort, dysregulated metabolites were validated and evaluated to see whether they could serve as biomarkers for 180-day poor outcomes by area under the curve (AUC).The primary cohort included 20 SSICH patients with good 180-day outcome and 20 with poor outcome. Untargeted metabolomics analysis found 25 co-dysregulated metabolites, including trimethylamine N-oxide (TMAO), among 3-day, 7-day, and 30day metabolism features between SSICH patients with poor outcome and good outcome after surgery. A good correlation was found in TMAO between serum and cerebrospinal fluid on 3 rd day after surgery. Based on the validation cohort of 794 SSICH patients (147 patients had 180-day poor outcome), the targeted metabolomics analysis revealed increasing TMAO on 3 rd day after surgery as a risk factor of poor outcomes (odds ratio, 4.7; 95%CI, 3.6-6.2; P<0.001), with a good predictive value (AUC, 0.81).This study demonstrated increasing serum TMAO level as an earlywarning biomarker for 180-day poor outcomes of SSICH patients receiving surgical treatment.
Keywords: Spontaneous intracerebral hemorrhage, surgical treatment, Poor outcome, Metabolomic analysis, Biomarker Trial registration: Chinese Clinical Trial Registry, ChiCTR1900024406,
Received: 02 Jan 2025; Accepted: 01 Apr 2025.
Copyright: © 2025 Sun, Zheng, Wang, Chen, Liu, Gu, Wu, Lu, Wang, Liu and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Shuo Wang, Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Qingyuan Liu, Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Zengguang Wang, Neurosurgery, Tianjin Medical University General Hospital, Tianjin, 300052, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.